Are you Dr. Rubinsak?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 64 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
901 Tamiami Trl S
Venice, FL 34285Phone+1 941-484-3531Fax+1 941-486-1701
Summary
- Dr. James Rubinsak, MD is an oncologist in Venice, Florida. He is currently licensed to practice medicine in Florida. He is affiliated with Venice Regional Bayfront Health.
Education & Training
- Keesler Medical CenterResidency, Internal Medicine, 1980 - 1983
- University of Mississippi School of MedicineClass of 1980
Certifications & Licensure
- FL State Medical License 1985 - 2018
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Sarasota Magazine: Top Doctors Castle Connolly, 2009-2014
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2014
Clinical Trials
- Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary Start of enrollment: 2009 Feb 01
Publications & Presentations
PubMed
- 8 citationsPhase II Study of Cetuximab, Docetaxel, and Gemcitabine in Patients With Previously Untreated Advanced Non–Small-Cell Lung CancerDavid R. Spigel, F. Anthony Greco, Dana S. Thompson, Charles D. Webb, James R. Rubinsak
Clinical Lung Cancer. 2010-05-01 - 26 citationsSingle-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.David R. Spigel, John D. Hainsworth, Emily R. Burkett, Howard A. Burris, Denise A. Yardley
Clinical Lung Cancer. 2005-09-01 - 60 citationsMarked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclop...James H. Essell, James M. Thompson, Glenn S. Harman, Ronald Halvorson, Michael J. Snyder
Blood. 1992-05-15